Grape King Bio Ltd (1707.TW)
TWD 151.0
(0.0%)
TWD 151.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.62 Billion TWD | -2.45% |
| 2022 | -4.51 Billion TWD | -34.24% |
| 2021 | -3.36 Billion TWD | -298.97% |
| 2020 | -843.03 Million TWD | -4.96% |
| 2019 | -803.21 Million TWD | 13.6% |
| 2018 | -929.66 Million TWD | -4.29% |
| 2017 | -891.43 Million TWD | -75.58% |
| 2016 | -507.7 Million TWD | -147.06% |
| 2015 | 1.07 Billion TWD | 178.9% |
| 2014 | -1.36 Billion TWD | -29.58% |
| 2013 | -1.05 Billion TWD | 1.23% |
| 2012 | -1.06 Billion TWD | -36.16% |
| 2011 | -784.63 Million TWD | -47.68% |
| 2010 | -531.31 Million TWD | -19.79% |
| 2009 | -443.53 Million TWD | -207.47% |
| 2008 | -144.25 Million TWD | -36.88% |
| 2007 | -105.38 Million TWD | -0.76% |
| 2006 | -104.59 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.65 Billion TWD | -0.64% |
| 2024 Q2 | -3.79 Billion TWD | 18.4% |
| 2023 Q1 | -4.49 Billion TWD | 0.43% |
| 2023 Q3 | -3.31 Billion TWD | 23.97% |
| 2023 Q2 | -4.35 Billion TWD | 3.05% |
| 2023 FY | -4.62 Billion TWD | -2.45% |
| 2023 Q4 | -4.62 Billion TWD | -39.59% |
| 2022 FY | -4.51 Billion TWD | -34.24% |
| 2022 Q1 | -3.33 Billion TWD | 0.73% |
| 2022 Q4 | -4.51 Billion TWD | -47.53% |
| 2022 Q3 | -3.06 Billion TWD | 0.87% |
| 2022 Q2 | -3.08 Billion TWD | 7.54% |
| 2021 Q1 | -2.61 Billion TWD | -209.99% |
| 2021 FY | -3.36 Billion TWD | -298.97% |
| 2021 Q3 | -2.06 Billion TWD | -16.62% |
| 2021 Q4 | -3.36 Billion TWD | -62.61% |
| 2021 Q2 | -1.77 Billion TWD | 32.13% |
| 2020 FY | -843.03 Million TWD | -4.96% |
| 2020 Q1 | -616.14 Million TWD | 23.29% |
| 2020 Q2 | -37.64 Million TWD | 93.89% |
| 2020 Q3 | 538.8 Million TWD | 1531.17% |
| 2020 Q4 | -843.03 Million TWD | -256.46% |
| 2019 Q1 | -539.02 Million TWD | 42.02% |
| 2019 Q2 | -454.95 Million TWD | 15.6% |
| 2019 Q3 | 344.65 Million TWD | 175.76% |
| 2019 Q4 | -803.21 Million TWD | -333.05% |
| 2019 FY | -803.21 Million TWD | 13.6% |
| 2018 FY | -929.66 Million TWD | -4.29% |
| 2018 Q4 | -929.66 Million TWD | -5069.09% |
| 2018 Q3 | -17.98 Million TWD | 95.56% |
| 2018 Q2 | -404.67 Million TWD | 54.27% |
| 2018 Q1 | -884.96 Million TWD | 0.73% |
| 2017 Q1 | -837.73 Million TWD | -65.0% |
| 2017 FY | -891.43 Million TWD | -75.58% |
| 2017 Q4 | -891.43 Million TWD | -364.48% |
| 2017 Q2 | -499.12 Million TWD | 40.42% |
| 2017 Q3 | -191.92 Million TWD | 61.55% |
| 2016 Q1 | 998.94 Million TWD | -7.41% |
| 2016 FY | -507.7 Million TWD | -147.06% |
| 2016 Q3 | 348.62 Million TWD | -53.52% |
| 2016 Q4 | -507.7 Million TWD | -245.63% |
| 2016 Q2 | 750.03 Million TWD | -24.92% |
| 2015 Q3 | 1.84 Billion TWD | 242.69% |
| 2015 FY | 1.07 Billion TWD | 178.9% |
| 2015 Q4 | 1.07 Billion TWD | -41.37% |
| 2015 Q2 | 536.95 Million TWD | 134.8% |
| 2015 Q1 | -1.54 Billion TWD | -12.85% |
| 2014 Q4 | -1.36 Billion TWD | -81.05% |
| 2014 Q2 | -652.05 Million TWD | 38.75% |
| 2014 Q1 | -1.06 Billion TWD | -0.87% |
| 2014 FY | -1.36 Billion TWD | -29.58% |
| 2014 Q3 | -755.26 Million TWD | -15.83% |
| 2013 Q4 | -1.05 Billion TWD | -58.34% |
| 2013 Q3 | -666.45 Million TWD | 26.82% |
| 2013 Q2 | -910.74 Million TWD | 16.04% |
| 2013 Q1 | -1.08 Billion TWD | -1.53% |
| 2013 FY | -1.05 Billion TWD | 1.23% |
| 2012 Q1 | -802.58 Million TWD | -2.29% |
| 2012 FY | -1.06 Billion TWD | -36.16% |
| 2012 Q2 | -652.51 Million TWD | 18.7% |
| 2012 Q3 | -837.3 Million TWD | -28.32% |
| 2012 Q4 | -1.06 Billion TWD | -27.6% |
| 2011 Q2 | -579.07 Million TWD | -14.35% |
| 2011 FY | -784.63 Million TWD | -47.68% |
| 2011 Q1 | -506.42 Million TWD | 4.68% |
| 2011 Q4 | -784.63 Million TWD | -56.69% |
| 2011 Q3 | -500.75 Million TWD | 13.52% |
| 2010 FY | -531.31 Million TWD | -19.79% |
| 2010 Q4 | -531.31 Million TWD | 0.0% |
| 2009 FY | -443.53 Million TWD | -207.47% |
| 2008 FY | -144.25 Million TWD | -36.88% |
| 2007 FY | -105.38 Million TWD | -0.76% |
| 2006 FY | -104.59 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | -384.506% |
| Maywufa Company Ltd. | 264.18 Million TWD | 1850.964% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | -39.313% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 147.135% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | -1795.634% |
| YungShin Global Holding Corporation | -247.5 Million TWD | -1768.996% |
| PhytoHealth Corporation | -34.64 Million TWD | -13253.492% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | 4706.574% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 282.233% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 74.949% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 336.425% |